A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

(DISCOVER-HCM Trial)

Recruiting in Palo Alto (17 mi)

+116 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Bristol-Myers Squibb

No Placebo Group

Breakthrough Therapy

Approved in 9 Jurisdictions

Trial Summary

What is the purpose of this trial?

This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment. United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting. Europe Sub-Study: The purpose of this study is to evaluate the effectiveness and safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.

Eligibility Criteria

Inclusion Criteria

I have been diagnosed with obstructive hypertrophic cardiomyopathy.

I have been diagnosed with obstructive hypertrophic cardiomyopathy.

I am 18 years old or older.

Treatment Details

Interventions

• Mavacamten (Myosin Inhibitor)
• Other Treatments (Other)

Participant Groups

Group I: Mavacamten Experimental Treatment 1 Intervention

Participants will receive mavacamten as prescribed by a physician according to standard of care for symptomatic oHCM

Group II: Beta-blocker (BB) / non-dihydropyridine (non-DHP) calcium channel blocker (CCB) / disopyramide Experimental Treatment 1 Intervention

Participants will receive BB/non-DHP CCB/disopyramide as prescribed by a physician according to standard of care for symptomatic oHCM

Mavacamten is already approved in United States, European Union, Canada, Australia, Switzerland, Brazil for the following indications:

🇺🇸 Approved in United States as Camzyos for:

• Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

🇪🇺 Approved in European Union as Camzyos for:

• Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

🇨🇦 Approved in Canada as Camzyos for:

• Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

🇦🇺 Approved in Australia as Camzyos for:

• Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

🇨🇭 Approved in Switzerland as Camzyos for:

• Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

🇧🇷 Approved in Brazil as Camzyos for:

• Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

AHN Allegheny General Hospital Pittsburgh, PA

MedStar Washington Hospital Center Washington, United States

UC San Diego School of Medicine La Jolla, CA

The Rector and Visitors of the Univ of Virginia Charlottesville, VA

More Trial Locations

Who Is Running the Clinical Trial?

Bristol-Myers Squibb Lead Sponsor

References